{"id":17569,"date":"2020-05-08T07:58:43","date_gmt":"2020-05-08T07:58:43","guid":{"rendered":"https:\/\/celonpharma.com\/?p=17569"},"modified":"2020-05-29T07:59:28","modified_gmt":"2020-05-29T07:59:28","slug":"4th-project-in-clinical-development-gpr40-with-the-consent-of-urplwmipb-to-launch-the-study","status":"publish","type":"post","link":"https:\/\/celonpharma.com\/en\/4th-project-in-clinical-development-gpr40-with-the-consent-of-urplwmipb-to-launch-the-study\/","title":{"rendered":"4th project in clinical development \u2013 GPR40 with the consent of URPLWMiPB to launch the study"},"content":{"rendered":"<p><span lang=\"EN-GB\">On 29 April 2020, we have received a positive decision from the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPLWMiPB) regarding an innovative GPR40 receptor agonist \u2013 CLP207280.<\/span><\/p>\n<p><span lang=\"EN-GB\">The clinical programme will be conducted in the treatment of metabolic diseases, including type II diabetes and diabetic neuropathies. The aim of the study will be to determine the safety and tolerability of the drug, as well as its pharmacokinetic properties after single and repeated administration and its interaction with metformin and food.<\/span><\/p>\n<p><span lang=\"EN-GB\">The drug is characterised by an extremely favourable safety profile in toxicological and preclinical studies, which distinguishes it from other drugs in this class.<\/span><\/p>\n<p><span lang=\"EN-GB\">The study is carried out as part of the GATE project, for which the Company was subsidised from the National Centre for Research and Development (POIR) in the amount of PLN 24.7 million.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>On 29 April 2020, we have received a positive decision from the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPLWMiPB) regarding an innovative GPR40 receptor agonist \u2013 CLP207280. The clinical programme will be conducted in the treatment of metabolic diseases, including type II diabetes and diabetic neuropathies. The aim of<a class=\"excerpt-read-more float-right\" href=\"https:\/\/celonpharma.com\/en\/4th-project-in-clinical-development-gpr40-with-the-consent-of-urplwmipb-to-launch-the-study\/\" title=\"Read4th project in clinical development \u2013 GPR40 with the consent of URPLWMiPB to launch the study\">Read more &raquo;<\/a><\/p>\n","protected":false},"author":20,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[30],"tags":[],"class_list":["post-17569","post","type-post","status-publish","format-standard","hentry","category-general-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>4th project in clinical development \u2013 GPR40 with the consent of URPLWMiPB to launch the study - Celon Pharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/celonpharma.com\/en\/4th-project-in-clinical-development-gpr40-with-the-consent-of-urplwmipb-to-launch-the-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"4th project in clinical development \u2013 GPR40 with the consent of URPLWMiPB to launch the study - Celon Pharma\" \/>\n<meta property=\"og:description\" content=\"On 29 April 2020, we have received a positive decision from the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPLWMiPB) regarding an innovative GPR40 receptor agonist \u2013 CLP207280. The clinical programme will be conducted in the treatment of metabolic diseases, including type II diabetes and diabetic neuropathies. The aim ofRead more &raquo;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/celonpharma.com\/en\/4th-project-in-clinical-development-gpr40-with-the-consent-of-urplwmipb-to-launch-the-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Celon Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2020-05-08T07:58:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-05-29T07:59:28+00:00\" \/>\n<meta name=\"author\" content=\"Ma\u0142gorzata Siewierska\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ma\u0142gorzata Siewierska\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/4th-project-in-clinical-development-gpr40-with-the-consent-of-urplwmipb-to-launch-the-study\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/4th-project-in-clinical-development-gpr40-with-the-consent-of-urplwmipb-to-launch-the-study\\\/\"},\"author\":{\"name\":\"Ma\u0142gorzata Siewierska\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/086a66251c93953fa818392fd883740c\"},\"headline\":\"4th project in clinical development \u2013 GPR40 with the consent of URPLWMiPB to launch the study\",\"datePublished\":\"2020-05-08T07:58:43+00:00\",\"dateModified\":\"2020-05-29T07:59:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/4th-project-in-clinical-development-gpr40-with-the-consent-of-urplwmipb-to-launch-the-study\\\/\"},\"wordCount\":154,\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/4th-project-in-clinical-development-gpr40-with-the-consent-of-urplwmipb-to-launch-the-study\\\/\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/4th-project-in-clinical-development-gpr40-with-the-consent-of-urplwmipb-to-launch-the-study\\\/\",\"name\":\"4th project in clinical development \u2013 GPR40 with the consent of URPLWMiPB to launch the study - Celon Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\"},\"datePublished\":\"2020-05-08T07:58:43+00:00\",\"dateModified\":\"2020-05-29T07:59:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/086a66251c93953fa818392fd883740c\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/4th-project-in-clinical-development-gpr40-with-the-consent-of-urplwmipb-to-launch-the-study\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/celonpharma.com\\\/en\\\/4th-project-in-clinical-development-gpr40-with-the-consent-of-urplwmipb-to-launch-the-study\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/4th-project-in-clinical-development-gpr40-with-the-consent-of-urplwmipb-to-launch-the-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"4th project in clinical development \u2013 GPR40 with the consent of URPLWMiPB to launch the study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/\",\"name\":\"Celon Pharma\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/celonpharma.com\\\/en\\\/#\\\/schema\\\/person\\\/086a66251c93953fa818392fd883740c\",\"name\":\"Ma\u0142gorzata Siewierska\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"4th project in clinical development \u2013 GPR40 with the consent of URPLWMiPB to launch the study - Celon Pharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/celonpharma.com\/en\/4th-project-in-clinical-development-gpr40-with-the-consent-of-urplwmipb-to-launch-the-study\/","og_locale":"en_US","og_type":"article","og_title":"4th project in clinical development \u2013 GPR40 with the consent of URPLWMiPB to launch the study - Celon Pharma","og_description":"On 29 April 2020, we have received a positive decision from the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPLWMiPB) regarding an innovative GPR40 receptor agonist \u2013 CLP207280. The clinical programme will be conducted in the treatment of metabolic diseases, including type II diabetes and diabetic neuropathies. The aim ofRead more &raquo;","og_url":"https:\/\/celonpharma.com\/en\/4th-project-in-clinical-development-gpr40-with-the-consent-of-urplwmipb-to-launch-the-study\/","og_site_name":"Celon Pharma","article_published_time":"2020-05-08T07:58:43+00:00","article_modified_time":"2020-05-29T07:59:28+00:00","author":"Ma\u0142gorzata Siewierska","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ma\u0142gorzata Siewierska","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/celonpharma.com\/en\/4th-project-in-clinical-development-gpr40-with-the-consent-of-urplwmipb-to-launch-the-study\/#article","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/4th-project-in-clinical-development-gpr40-with-the-consent-of-urplwmipb-to-launch-the-study\/"},"author":{"name":"Ma\u0142gorzata Siewierska","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/086a66251c93953fa818392fd883740c"},"headline":"4th project in clinical development \u2013 GPR40 with the consent of URPLWMiPB to launch the study","datePublished":"2020-05-08T07:58:43+00:00","dateModified":"2020-05-29T07:59:28+00:00","mainEntityOfPage":{"@id":"https:\/\/celonpharma.com\/en\/4th-project-in-clinical-development-gpr40-with-the-consent-of-urplwmipb-to-launch-the-study\/"},"wordCount":154,"articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/celonpharma.com\/en\/4th-project-in-clinical-development-gpr40-with-the-consent-of-urplwmipb-to-launch-the-study\/","url":"https:\/\/celonpharma.com\/en\/4th-project-in-clinical-development-gpr40-with-the-consent-of-urplwmipb-to-launch-the-study\/","name":"4th project in clinical development \u2013 GPR40 with the consent of URPLWMiPB to launch the study - Celon Pharma","isPartOf":{"@id":"https:\/\/celonpharma.com\/en\/#website"},"datePublished":"2020-05-08T07:58:43+00:00","dateModified":"2020-05-29T07:59:28+00:00","author":{"@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/086a66251c93953fa818392fd883740c"},"breadcrumb":{"@id":"https:\/\/celonpharma.com\/en\/4th-project-in-clinical-development-gpr40-with-the-consent-of-urplwmipb-to-launch-the-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/celonpharma.com\/en\/4th-project-in-clinical-development-gpr40-with-the-consent-of-urplwmipb-to-launch-the-study\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/celonpharma.com\/en\/4th-project-in-clinical-development-gpr40-with-the-consent-of-urplwmipb-to-launch-the-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/celonpharma.com\/en\/"},{"@type":"ListItem","position":2,"name":"4th project in clinical development \u2013 GPR40 with the consent of URPLWMiPB to launch the study"}]},{"@type":"WebSite","@id":"https:\/\/celonpharma.com\/en\/#website","url":"https:\/\/celonpharma.com\/en\/","name":"Celon Pharma","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/celonpharma.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/celonpharma.com\/en\/#\/schema\/person\/086a66251c93953fa818392fd883740c","name":"Ma\u0142gorzata Siewierska"}]}},"_links":{"self":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/17569","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/comments?post=17569"}],"version-history":[{"count":1,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/17569\/revisions"}],"predecessor-version":[{"id":17570,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/posts\/17569\/revisions\/17570"}],"wp:attachment":[{"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/media?parent=17569"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/categories?post=17569"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/celonpharma.com\/en\/wp-json\/wp\/v2\/tags?post=17569"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}